Skeletal Muscle Mitochondrial DNA Injury in Patients With Unilateral Peripheral Arterial Disease

Hari K. Bhat, PhD; William R. Hiatt, MD; Charles L. Hoppel, MD; Eric P. Brass, MD, PhD

Background—Patients with peripheral arterial disease (PAD) have exercise limitation due to claudication-limited pain and metabolic alterations in skeletal muscle. PAD is also associated with oxidative stress, which is a known cause of mitochondrial DNA (mtDNA) injury. The present study was designed to test the hypothesis that PAD is associated with mtDNA injury, as reflected by an increased frequency of a specific 4977-base pair (bp) mtDNA deletion mutation.

Methods and Results—The deletion frequency was quantified in gastrocnemius muscle of 8 patients with unilateral PAD and 10 age-matched control subjects with the use of polymerase chain reaction methodologies. Muscle from the hemodynamically unaffected (less affected) PAD limb showed an 8-fold increased deletion frequency and the hemodynamically affected (worse affected) PAD limb had a 17-fold increased deletion frequency compared with muscle from control subjects. The frequency of the 4977-bp deletion in the worse-affected limb was positively correlated with the age of the patients but not the claudication-limited exercise performance of the patients. Total mtDNA content, citrate synthase activity, and cytochrome c oxidase activity were not different in the muscle from the 3 limb populations. However, the ratio of citrate synthase to cytochrome c oxidase was higher in the worse- versus less-affected limbs of PAD patients.

Conclusions—The present study demonstrates a large increase in the frequency of the mtDNA 4977-bp deletion in patients with PAD but in a distribution not limited to the hemodynamically affected limb. (Circulation. 1999;99:807-812.)

Key Words: peripheral vascular disease ■ aging ■ metabolism

Peripheral arterial disease (PAD) results from atherosclerotic occlusion and impairment of arterial oxygen delivery to the lower limb and is associated with development of claudication pain with exercise.2,3 Although the initial insult in PAD is circulatory, peripheral hemodynamics are poor predictors of exercise capacity in PAD patients.4 Thus, factors intrinsic to the skeletal muscle may contribute to the functional impairment of patients with PAD.

Metabolic changes occur in the skeletal muscle of PAD patients.5-7 Muscle mitochondrial enzyme expression is altered,5,8,9 intermediates of oxidative metabolism accumulate,5,10 the kinetic response to exercise is slowed,11 and exercise training is abnormal12,13 in these patients. These metabolic features are similar to those in mitochondrial myopathies7,11 and suggest functionally relevant metabolic sequelae from the chronic hemodynamic abnormalities in PAD patients.

Somatic mutations to mitochondrial DNA (mtDNA) have been hypothesized to cause acquired mitochondrial dysfunction.14,15 mtDNA encodes for 13 polypeptides critical for electron transport chain function.14,16 Well-characterized mtDNA mutations arise from mutation hot spots.17,18 A 4977-base pair (bp) deletion spanning mtDNA nucleotide pairs 8469 to 13447 (standard human mitochondrial DNA nomenclature used throughout; see Reference 16) has been reported frequently.14,19-21 Because each mitochondrion contains multiple copies of the genome,14 injury results in heteroplasmy in which each cell contains mtDNA molecules with varied sequences.14,22 Increased mtDNA mutation frequency occurs in humans with aging23-25 and in ischemic myocardium.19,21 The impact of acquired mtDNA injury in disease pathophysiology has been difficult to define owing to the lack of data relating mtDNA injury to mitochondrial and tissue function.

PAD provides a unique model for assessing the importance of mtDNA mutations in a clinically important disease. PAD is associated with oxidative stress26,27 analogous to the suggested mtDNA injury mechanism in ischemic heart.14,19,21 Patients with unilateral PAD permit specific influences of ischemia on mtDNA mutation frequency to be defined. Exercise testing and measurement of mitochondrial enzyme activities permits functional measurements as well. The present study was designed to test the hypothesis that PAD is associated with mtDNA injury, as reflected by an increased frequency of the specific 4977-bp mtDNA deletion.

Received May 27, 1998; revision received September 4, 1998; accepted September 25, 1998.

From the Department of Medicine, Harbor-UCLA Medical Center (H.K.B., E.P.B.), Torrance, Calif; University of Colorado Health Sciences Center (W.R.H.), Denver, Colo, and Cleveland VA Medical Center (C.L.H.), Departments of Pharmacology and Medicine, Case Western Reserve University, Cleveland, Ohio.

Correspondence to Eric P. Brass, MD, PhD, Department of Medicine, Harbor-UCLA Medical Center, 1000 W Carson St, Torrance, CA 90509. E-mail ebrass@ucla.edu

© 1999 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org
Methods

Patients
Eight patients with unilateral PAD and 10 age-matched, sedentary control subjects were recruited. A history and physical examination were performed, and subjects underwent assessment of ankle/brachial index (ABI; ratio of systolic blood pressures in ankle to arm). Unilateral PAD was identified as previously described.28 The limb with hemodynamically determined PAD is referred to as the “worse-affecte limb” and the limb with ABI in the normal range is referred to as “less affected.” All subjects underwent graded treadmill testing and peak oxygen uptake (VO2) measurement.13,22,28 PAD subjects underwent needle biopsies of each gastrocnemius muscle at rest as described.6,13 Eight control subjects had a muscle sample taken from 1 leg, and 2 control subjects had a muscle sample taken from both legs. Samples were immediately frozen in liquid nitrogen and stored at −80°C until analysis. All protocols were approved by appropriate Institutional Review Boards, and all subjects gave informed consent.

4977-bp Deletion Frequency
Total cellular DNA was extracted from 10 to 20 mg of frozen muscle by use of a QIAamp kit (Qiagen, Inc). Before polymerase chain reaction (PCR) amplification, DNA samples were digested with PstI (acting at nucleotide pairs 6910 and 9020) and HindIII (acting at nucleotide pairs 6203, 11 680, and 12 567) (Promega, Inc) for 16 hours at 37°C to linearize the mtDNA and cut the sequence within the 4977-bp deletion region.19 The digested DNA was extracted with phenol/chloroform, precipitated, and washed with ethanol, dissolved in Tris-HCl, 10 mmol/L, pH 9.0, and remeasured before dilution and use.

The proportion of total mtDNA containing a specific 4977-bp deletion (deletion of 8469 to 13 447 nucleotide pairs16) was determined with a serial dilution PCR method modified from Corral-Debrinski et al.19 Two sets of PCR reactions were performed on each sample. For the first amplification, primers amplified a region not affected by the 4977-bp deletion or any other known mtDNA sequence variation over the range of 2 to 200 ng per tube for the deletion and yielded a 593-bp product only if the 4977-bp deletion was present (5'-GTT GAG TTC CTC CTC CCT GTA CGC GCA AGT GAA ATC TCC-3' [primer 1], complementary to bases 3108 to 3127, and 5'-TTG GCC TGG CTT TGC TCG CAG TG-3' [primer 2], complementary to bases 3701 to 3720). This amplification yields a 613-bp product from both wild-type and mtDNA containing the 4977-bp deletion and is termed the total mtDNA product. The second set of primers flanked the 4977-bp deletion and yielded a 593-bp product only if the 4977-bp deletion was present (5'-CTC TAG AGC CCA CTG TAA AGC TAA-3' [primer 3], complementary to bases 8283 to 8305, and 5'-GTC TAG GGC TAC TGC-3' [primer 4], complementary to bases 13 832 to 13 851). PCR amplifications (100 μL total volume) contained 200 μmol/L of each dNTP, 1.5 mmol/L MgCl2, 10 mmol/L Tris-HCl, and 50 mmol/L KCl, 0.3 μmol/L primers, and 5 U of Taq polymerase (Boehringer Mannheim). For PCR amplification of the 613-bp total mtDNA product, conditions were 2 minutes of denaturation at 94°C (reduced to 1 minute in the second cycle and 30 seconds in 33 subsequent cycles), 2 minutes of annealing at 51°C, and 2 minutes of polymerization at 72°C. After 35 cycles, a 7-minute extension at 72°C was performed. Amplification of the 593-bp deletion product was conducted under the same conditions except that annealing was performed at 56°C.19 Ethidium bromide-stained 2% agarose fractionation gels were photographed, and negative films were quantified with a Bio-Rad GS-700 imaging densitometer (Bio-Rad Laboratories). Each gel included a DNA mass ladder (Gibco BRL) in duplicate. The signal for the 800-bp fragment was used as a standard and to normalize the signal for each PCR product. For each sample, the PCR reactions were run at a minimum of 6 different DNA template concentrations (typically varying over the range of 2 to 200 ng per tube for the deletion amplification and 0.001 to 5 ng per tube for the total mtDNA amplification), which permitted generation of a product optical density (OD) versus template concentration curve. The ratio of the template DNAs required to yield the same amount of product was used as a measure of the relative amounts of deleted mtDNA versus total mtDNA in the sample (Figure 1).

This method demonstrated similar PCR amplification efficiencies for the deletion-specific and wild-type reactions, and no 593-bp deletion product was detected in DNA from young healthy subjects (<0.01% frequency). The coefficient of variation was found to be 20% when a single sample was run multiple times on separate days. The validated lower limit of detection was 0.01%, and thus all estimates that yielded deletion frequencies <0.01% were conservatively reported as 0.01%.

Total mtDNA Content
A competitive PCR strategy was used for the measurement of total mtDNA.20 A 500-bp internal standard was generated with a PCR-MIMIC construction kit from Clontech with a nonhomologous DNA fragment of known sequence. The internal standard fragment was generated with 2 rounds of PCR amplification reactions, the first with composite primers and the second with mtDNA-specific primers. Composite (40-mer) upstream and downstream primers were designed such that each composite primer consisted of a 20-nucleotide base mtDNA template-specific sequence, followed by a 20-nucleotide base sequence complementary to the MIMIC DNA fragment (5'-TTA AAA TTC CTC CCT GTA CCG ACC GAC ATC TCG CCG-3', composite upstream primer 5, and 5'-GTG GCC TGG CTT TGC TCG CAG TTA TAC TTA CCT GCA AGC A-3', composite downstream primer 6). The PCR product generated was then used in a second round of PCR amplification with mtDNA-specific primers (primers 1 and 2 used for the amplification of the 613-bp total mtDNA product, discussed above) to provide the internal standard.

Various amounts of internal standard DNA fragment (typically 6.0×105 to 6.0×107 molecules, including at least 6 different concentrations) were added to a known amount of total muscle DNA (typically 0.01 to 0.1 ng). PCR amplification was performed for 30 cycles with primers 1 and 2 under conditions for the amplification of the 613-bp mtDNA product as described above, except that the primer concentration was 0.6 μmol/L. This reaction thus yielded the 613-bp product from mtDNA and a 500-bp fragment from the competitor template. The PCR reaction products were separated on 2% agarose gel, negative films of the ethidium bromide stained gels were measured by densitometry, and the logs of the ratio of the
TABLE 1. Characteristics of Control Subjects and PAD Patients

<table>
<thead>
<tr>
<th></th>
<th>Control (n=10)</th>
<th>PAD (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>61±3</td>
<td>63±4</td>
</tr>
<tr>
<td>Smoking status, n</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smokers</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Former smokers</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>ABI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rest</td>
<td>1.10±0.02</td>
<td>Less: 1.09±0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Worse: 0.50±0.05*†</td>
</tr>
<tr>
<td>After exercise</td>
<td>ND</td>
<td>Less: 1.00±0.06</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Worse: 0.25±0.05*</td>
</tr>
<tr>
<td>Peak VO2, mL·min⁻¹·kg⁻¹</td>
<td>28.4±2.0</td>
<td>14.3±0.8†</td>
</tr>
</tbody>
</table>

Less indicates less-affected limb; Worse, worse-affected limb; and ND, not determined.

Values are mean±SEM. *P<0.05 less vs worse; †P<0.05 vs control.

mtDNA-specific product and internal standard ODs were plotted against the log of molecules of internal standard added to the reaction. We calculated the mtDNA content by determining the x intercept for the point at which the ratio of the 613- and 500-bp products was 1 (log 0).

**Enzyme Assays**

Muscle homogenates (10 mg/mL) of frozen tissue prepared in 220 mmol/L mannitol, 70 mmol/L sucrose, 10 mmol/L MOPS, and 1% cholate (pH 7.0) were used for enzyme and protein assays. Citrate synthase activity was determined by the method of Srere,31 and noncollagenase protein by the method of Lilienthal et al.33

**Statistical Analysis**

Data are expressed as mean±SEM. Student’s t test (paired) was used to compare data for the worse- and less-affected limbs of PAD patients, and unpaired t tests were used for comparison between PAD and control subjects. Analyses of the 4977-bp deletion frequency data were prospectively based on log-transformed values to yield a normally distributed population. The values for both legs were averaged before population analyses were performed for control subjects biopsied in each leg.

**Results**

All PAD and control subjects were male and of similar age (Table 1). PAD patients had a peak oxygen consumption only 50% that of the control subjects. The ABI of the less-affected limb in the PAD subjects did not differ from controls, whereas the worse-affected limb had an ABI <50% of the control value. The PAD group included more smokers and as a group had a heavier smoking history than the control subjects (22.5±6.9 pack-years and 44.2±8.1 pack-years in control and PAD subjects, respectively; P<0.05).

As expected, the gastrocnemius muscle from the control subjects showed a low (0.05%) 4977-bp deletion frequency (Table 2). In contrast, the less-affected PAD limbs showed an 8-fold higher deletion frequency than controls (P<0.05), and the worse-affected PAD limbs demonstrated a 17-fold higher deletion frequency than control subjects (P<0.01; Table 2). The frequency of the deletion was not different in worse-affected limbs versus less-affected limbs in the PAD population (P=0.119). Six of the 8 PAD subjects had higher deletion frequencies in the worse- versus less-affected limbs (Figure 2). Significant overlap was seen in the deletion frequencies in the worse- and less-affected limbs among the 8 patients (Figure 2). The deletion frequencies in the patients’ less-affected and worse-affected limbs were strongly correlated (r=0.88, P<0.01).

The frequency of the 4977-bp deletion in the worse-affected limbs from the PAD population was positively correlated with age (Figure 3). A similar correlation of lesser slope was seen in the less-affected limb (log deletion frequency=0.0468×age−5.78; r=0.735). The low deletion frequency in the control muscles precluded a meaningful correlation analysis in this population. There were no significant relationships between the 4977-bp deletion frequency in the worse-affected limbs and either the patients’ ABI or claudication-limited exercise performance.

Muscle mitochondrial expression is closely linked to total mtDNA content.34,35 No significant differences in the total mtDNA content were found between control subjects and the less- or worse-affected limbs of PAD patients (Table 2). No differences in the activity of citrate synthase or cytochrome c

**TABLE 2. Frequency of the 4977-bp mtDNA Deletion**

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Less-Affected Limb</th>
<th>Worse-Affected Limb</th>
</tr>
</thead>
<tbody>
<tr>
<td>% mtDNA with 4977-bp deletion</td>
<td>0.05±0.01</td>
<td>0.43±0.28*</td>
<td>0.88±0.33*</td>
</tr>
<tr>
<td>mtDNA, molecules×10⁶/ng DNA</td>
<td>1.15±0.14</td>
<td>1.01±0.22</td>
<td>0.89±0.12</td>
</tr>
</tbody>
</table>

*P<0.05 compared with control values. Values are mean±SEM.
Mitochondrial DNA Injury in PAD

Figure 3. Frequency of the 4977-bp deletion in worse-affected limbs of patients with PAD vs age. Deletion frequency in worse-affected limb from each patient is plotted (log scale) as a function of the patient’s age. Least squares regression line is shown (log [deletion frequency]=0.0478×age−5.62; r=0.689).

The 4977-bp mtDNA deletion is increased in PAD but is not specific for the ischemic limb. The 17-fold increase in frequency of the 4977-bp deletion in the worse-affected limb of the PAD subjects compared with controls is consistent with the increased deletion frequency seen in ischemic myocardium22,24 and the preliminary observations of Egawhary et al36 in nonmuscle cells in PAD.

The most severely affected individual demonstrated a deletion frequency 88-fold higher than the control group mean (Figure 2) and 440-fold higher than the individuals at the low end of the control group range (data not shown). The 4977-bp deletion was correlated with the patient’s age (Figure 3). The frequency of this deletion is increased in a variety of settings, including enhanced free radical generation.24,37 Ischemia and ischemia/reperfusion are associated with increased free radical generation from the mitochondrial electron transport chain,38,39 and PAD is associated with a state of increased oxidative stress.26,27

There was a strong trend for a higher deletion frequency in the worse- versus less-affected limb in individual patients (2-fold higher absolute mean deletion frequency, P=0.119, with 6 of 8 paired limbs demonstrating the relationship; Figure 2). The current study was not powered to detect differences in deletion frequency of this small magnitude (a total of ~20 patients would be required), and thus the lack of statistical significance may be misleading. Nonetheless, the major increase in mtDNA injury appears to be independent of local ischemia in the PAD population. Smoking is prevalent in the PAD population and has been hypothesized to accelerate mtDNA injury.40 However, the control group contained smokers, and no difference in 4977-bp deletion frequency within the control group as a function of smoking was identified (data not shown). Alternatively, mtDNA injury in the less-affected limb may reflect subclinical arterial disease that is sufficient to induce injury mechanisms despite the lack of symptoms and ABIs in the normal range. This is unlikely given the strong relationship between the degree of mtDNA injury in the less-affected limb and the injury in the worse-affected muscle (Figure 2). Thus, the oxidative stress associated with PAD26,27 appears to induce mtDNA damage in a distribution beyond the ischemic vascular bed, which may be further aggravated by ischemia in the affected limb.

TABLE 3. Enzyme Activities for Citrate Synthase and Cytochrome Oxidase

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Less-Affected Limb</th>
<th>Worse-Affected Limb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citrate synthase, μmol · min⁻¹ · g protein⁻¹</td>
<td>133±13</td>
<td>108±10</td>
<td>145±22</td>
</tr>
<tr>
<td>Cytochrome c oxidase, min⁻¹ · mg⁻¹</td>
<td>2.12±0.29</td>
<td>1.86±0.31</td>
<td>1.96±0.29</td>
</tr>
<tr>
<td>Citrate synthase/cytochrome c oxidase, μmol citrate synthase · min⁻¹</td>
<td>71±10</td>
<td>66±9</td>
<td>78±7*</td>
</tr>
</tbody>
</table>

*P<0.05 compared with less-affected limb. Values are mean±SEM.
hemodynamics, and biochemical abnormalities between the 2 limbs.6 Assessment of mtDNA injury in only the diseased limb might have suggested that mtDNA injury was relevant to the pathogenesis of the myopathy of PAD. However, examination of the less-affected limb makes this hypothesis less tenable. The high degree of mtDNA injury in the less-affected limb of some subjects and the overlap in deletion frequency in the less- versus worse-affected limb population (Figure 2) make a primary role for mtDNA injury in the disease unlikely. The deletion frequency in the worse-affected limb was not correlated with either the patient’s hemodynamics (ABI) or claudication-limited function. Similarly, cytochrome c oxidase activity was not decreased in the less-affected limb of some subjects and the overlap in activity make it unlikely that a simple model of mtDNA injury, as evidenced by the high 4977-bp mtDNA deletion frequency, but this injury is not limited to the worse-affected limb in patients with unilateral disease. mtDNA injury in the less-affected limb and the relative preservation of mtDNA content and cytochrome c oxidase activity make it unlikely that a simple model of mtDNA injury causing decreased expression is responsible for the metabolic derangements seen in PAD.

In summary, PAD is associated with accumulation of mtDNA injury, as evidenced by the high 4977-bp mtDNA deletion frequency, but this injury is not limited to the worse-affected limb in patients with unilateral disease. mtDNA injury in the less-affected limb and the relative preservation of mtDNA content and cytochrome c oxidase activity make it unlikely that a simple model of mtDNA injury causing decreased expression is responsible for the metabolic derangements seen in PAD.

Acknowledgment
This study was supported in part by the Harbor-UCLA Research and Education Institute, Sandoz Gerontological Foundation, Sigma Tau Pharmaceuticals, NIH Award in Vascular Medicine (NIH HL-02825), and the American Heart Association, Greater Los Angeles Affiliate, Los Angeles, Calif. The authors thank Kalpana Patel and Timothy Bauer for their technical help.

References
5. Janssens E, Johansson I, Sylven C, Kaisjer L. Calf muscle adaptation in intermittent claudication: side-differences in muscle metabolic character-


Skeletal Muscle Mitochondrial DNA Injury in Patients With Unilateral Peripheral Arterial Disease
Hari K. Bhat, William R. Hiatt, Charles L. Hoppel and Eric P. Brass

Circulation. 1999;99:807-812
doi: 10.1161/01.CIR.99.6.807

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/99/6/807